Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

9 terminated/withdrawn out of 63 trials

Success Rate

83.6%

-2.9% vs industry average

Late-Stage Pipeline

32%

20 trials in Phase 3/4

Results Transparency

39%

18 of 46 completed trials have results

Key Signals

5 recruiting18 with results8 terminated

Enrollment Performance

Analytics

Phase 1

23(39.0%)

Phase 2

14(23.7%)

Phase 3

14(23.7%)

Phase 4

6(10.2%)

N/A

2(3.4%)

59Total

Phase 1(23)

Phase 2(14)

Phase 3(14)

Phase 4(6)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (63)

Showing 20 of 63 trials

NCT07224321Phase 2Recruiting

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

Role: lead

NCT07344558Phase 1Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Role: lead

NCT06418711Phase 3Terminated

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Role: lead

NCT06880835Not ApplicableRecruiting

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

Role: collaborator

NCT06535789Phase 2Recruiting

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Role: collaborator

NCT04974528Phase 3Completed

Afrezza® INHALE-1 Study in Pediatrics

Role: lead

NCT05243628Phase 4Completed

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

Role: lead

NCT05904743Phase 4Completed

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Role: lead

NCT06532942Phase 1Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

Role: lead

NCT03324776Phase 3Completed

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

Role: collaborator

NCT04849845Phase 4Completed

Afrezza® Dosing Optimization Study

Role: lead

NCT03143816Phase 4Completed

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

Role: collaborator

NCT02527265Phase 2Completed

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Role: lead

NCT04125082Phase 4Unknown

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

Role: collaborator

NCT03313960Phase 4Unknown

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

Role: collaborator

NCT03464864Phase 1Completed

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Role: lead

NCT00642616Phase 3Terminated

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Role: lead

NCT02470637Phase 1Completed

Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

Role: lead

NCT02485327Phase 1Completed

PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

Role: lead

NCT01798914Unknown

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Role: lead